---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-013563"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:12:11.333741+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin

## Summary
- 50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.
- 25 mg cohort: median FXN increase in skin 2.81 pg/µg; one allergic AE resolved; 18 of 19 completed.
- Cash $86.8M as of Dec 31, 2023; expected runway into Q1 2025.
- OLE initiated Jan 2024 starting 25 mg daily; interim data expected Q4 2024.
- FDA discussions ongoing for accelerated approval using FXN as surrogate; BLA submission targeted 2H 2025.

## SEC filing metadata
- accession: 0000950170-24-013563
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024013563/0000950170-24-013563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024013563/lrmr-20240212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-013563
- JSON: https://secwatch.observer/filing/0000950170-24-013563.json
- Plain text: https://secwatch.observer/filing/0000950170-24-013563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.